The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality
The FDA placed BPC-157 in Category 2 in 2023 and removed it on April 22, 2026, ahead of a PCAC review in July 2026, but it is still not FDA-approved
(2001) tested BPC-157 on rats consuming alcohol daily for three months at 7.28 g/kg per day
The research is strongest in soft-tissue repair and gastrointestinal protection models, with evidence showing benefit in tendon healing, ligament repair, muscle injury, wound healing, angiogenesis, inflammatory modulation, and gut mucosal protection
The additional adipose tissue in heavier individuals creates a larger target for the peptide but also means more tissue requires the signal to release stored lipids